Skip to main content
OpenTrials
Completed

NCT Number: NCT00162799

Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity

To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet). The hypothesis is to explore if there is a reduction of obesity-induced insulin resistance by triflusal.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Insulin Resistance Glucose Metabolism Disorders Hyperinsulinism Metabolic Diseases Nutritional and Metabolic Diseases

Age range

35 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Unitat de Diabetologia, Endocrinologia y Nutrición Hosp Josep Trueta

Girona, 17007, Spain

About this study

Double-blind, randomized, cross-over (three periods) with two dose levels of triflusal, placebo-controlled.

Interventions: treatment periods Triflusal 600 mg/d, 15 days Triflusal 900 mg/d , 15 days placebo, 15 days

Washout period: 30 days

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages 35 to 60 years old

Treatment and study plan

Triflusal (DCI)

Drug

Primary outcomes

  1. Increase of insulin sensitivity in apparently healthy men and woman evaluate by means of i.v. glucose tolerance test (PTEVGMR).

Secondary outcomes

  1. Reduction antropometric measures associated with insulin resistance and arterial hypertension.

Sponsors and collaborators

Lead sponsor

J. Uriach and Company

Industry

Registry information

Official study title

Phase IIa Study of Triflusal in the Attenuation of Insulin Resistance in Men and Woman With Obesity

Important dates

Study start
2002
Study completion
2004
First posted
Sep 13, 2005
Registry last updated
Jun 23, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.